Literature DB >> 29793821

Epidemiology and patient-reported outcome after juvenile osteochondritis dissecans in the knee.

Archana Ananthaharan1, Per-Henrik Randsborg2.   

Abstract

BACKGROUND: This study describes the epidemiology and patient reported outcomes following juvenile osteochondritis dissecans (JOCD) of the knee.
METHODS: Medical records and radiographs of patients aged 10-18years diagnosed with JOCD between 2010 and 2016 were retrospectively reviewed. The lesions were classified according to the International Cartilage Repair Society's classification. The results were evaluated with the Knee injury and Osteoarthritis Outcome Score (KOOS), the Lysholm score and a Visual Analogue Scale (VAS) for pain.
RESULTS: Seventy patients with 87 JOCDs were identified. The annual incidence was 11.5 (95% confidence interval 10.7-12.2) per 100,000 inhabitants younger than 19years. Fifty-two (74.3%) of the 70 patients returned the questionnaires on average 48months (five to 117) after diagnosis. The median Lysholm score was 84 for patients with grade I-II lesions and 80 for patients with grade III-IV lesions. The median Lysholm score was 84.5 for patients who were treated conservatively and 79.5 for patients who were treated operatively. The median VAS score was 2.0 for all groups, except for patients treated conservatively (median score 1.5). Conservative treatment was successful in 78% of grade I-II lesions. There was a fivefold increased risk of failing conservative treatment with a stage III-IV lesion, compared to stage I-II (Odds ratio=5.5, p=0.02).
CONCLUSIONS: The results following JOCD are good to excellent for the majority of patients. Grade I-II lesions are successfully treated conservatively in 78% of cases. Grade III-IV lesions have a high failure rate. LEVEL OF EVIDENCE: Level III, retrospective cohort.
Copyright © 2018 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Epidemiology; KOOS; Lysholm; Osteochondritis dissecans; Patient reported outcome

Mesh:

Year:  2018        PMID: 29793821     DOI: 10.1016/j.knee.2018.02.005

Source DB:  PubMed          Journal:  Knee        ISSN: 0968-0160            Impact factor:   2.199


  7 in total

1.  Juvenile Osteochondritis Dissecans of the Knee Joint: Midterm Clinical and MRI Outcomes of Arthroscopic Retrograde Drilling and Internal Fixation with Bioabsorbable Pins.

Authors:  Georgios Komnos; Michael Iosifidis; Fotios Papageorgiou; Ioannes Melas; Dimitrios Metaxiotis; Michael Hantes
Journal:  Cartilage       Date:  2021-04-24       Impact factor: 3.117

2.  Health State Utilities in Children and Adolescents With Osteochondritis Dissecans of the Knee.

Authors:  Joshua Adjei; Benedict U Nwachukwu; Yi Zhang; Huong T Do; Daniel W Green; Emily R Dodwell; Peter D Fabricant
Journal:  Orthop J Sports Med       Date:  2019-12-05

3.  Arthroscopic Fixation of Osteochondritis Dissecans of the Knee Using a Motorized Pick and Headless Compression Screws.

Authors:  Per-Henrik Randsborg; Stian Kjennvold; Jan Harald Røtterud
Journal:  Arthrosc Tech       Date:  2019-09-19

4.  Variable expressivity in a family with an aggrecanopathy.

Authors:  Antoine Denis; Sami Chergui; Shuaa Basalom; Philippe M Campeau; Chantal Janelle; Thierry Pauyo
Journal:  Mol Genet Genomic Med       Date:  2021-12-10       Impact factor: 2.183

5.  Osteochondral Allograft for Unsalvageable Osteochondritis Dissecans in the Skeletally Immature Knee.

Authors:  Breann Tisano; Henry B Ellis; Chuck Wyatt; Philip L Wilson
Journal:  Orthop J Sports Med       Date:  2022-02-11

6.  Arthroscopic Drilling for Stable Juvenile Osteochondritis Dissecans of the Knee Is Safe and Patients Reliably Return to Daily Activities by 3 Months.

Authors:  Soroush Baghdadi; David Isaacs; Calvin T Chan; Lawrence Wells; Theodore J Ganley; J Todd R Lawrence
Journal:  Arthrosc Sports Med Rehabil       Date:  2022-02-15

7.  Adjunct use of radiofrequency coblation for osteochondritis dissecans in children: A case report.

Authors:  Reed Estes
Journal:  Medicine (Baltimore)       Date:  2020-08-28       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.